Fresenius Completes Acquisition of mAbxience, Creating a Stronger Platform for Future Portfolio Expansion
Fresenius said full ownership will strengthen biosimilars development and supply as the next wave of biologics loses exclusivity.
- On Thursday, October 1, 2026, Fresenius SE & Co. KGaA acquired the remaining 45% of mAbxience from Insud Pharma, completing full ownership of the biosimilars platform in Madrid.
- Fresenius Chief Executive Officer Michael Sen noted the acquisition follows a four-year investment, stating full ownership provides 'complete control over cost, capacity and launch timing' as biologics lose exclusivity.
- This transaction integrates the platform fully into Fresenius Kabi's Biopharma business, which manages the entire value chain from development and manufacturing through to commercialization, enhancing supply resilience.
- Jurgen van Broeck, Chief Executive Officer of mAbxience, will continue to lead the business, reporting to Dr. Sang-Jin Pak, President Biopharma at Fresenius, ensuring continuity.
- Combining the organizations enables a stronger platform to support future innovation and expanded patient access to biosimilars, leveraging the entrepreneurial spirit and scientific expertise that have defined mAbxience's success.
14 Articles
14 Articles
The medical and hospital group takes over its biopharma subsidiary mAbxience completely for a lot of money and thus strengthens an important business. However, there is one condition for 50 million of these.
saarbruecker-zeitung.de
The medical and hospital group takes over its biopharma subsidiary mAbxience completely for a lot of money and thus strengthens an important business. However, there is one condition for 50 million of these.
Here you will find information on the topic "Dax Group". Read now "Fresenius completely swallows biopharma subsidiary mAbxience".
Cecil Daily
PR NewswireFresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion
The transaction builds on the successful partnership between Fresenius and mAbxience established in 2022.Full ownership creates a stronger platform to enhance quality and supply resilience, while supporting future innovation and broader patient access to high-quality biosimilars.mAbxience will continue supporting its…
(Teleborsa) - Fresenius, German colossus of medical services, announced the acquisition of the remaining 45% of mAbxience from Insud Pharma and Corporate Invim, for a total consideration of up to 750 million...
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
